Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
JW Shinyak is a South Korean pharmaceutical company and a key subsidiary of JW Holdings. The company specializes in the development, manufacturing, and marketing of ethical (ETC) and over-the-counter (OTC) drugs, maintaining a dominant market position in dermatology, urology, and otolaryngology. Its product portfolio is particularly well-known for hair loss treatments, including the finasteride-based Monad and dutasteride-based Monaland. Through its subsidiary JW CreaGene, the company also explores advanced biotechnology, specifically dendritic cell-based immunotherapies for various cancers. JW Shinyak continues to expand its presence in the aesthetics and healthcare markets through strategic partnerships and a robust distribution network.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on JW Shinyak.